BIOTECH AND GENETICS INDUSTRY
CONTENTS INTRODUCTION HOW TO USE THIS BOOK CHAPTER 1: MAJOR TRENDS AFFECTING THE BIOTECH & GENETICS INDUSTRY 1) THE STATE OF THE BIOTECHNOLOGY INDUSTRY TODAY 2) A SHORT HISTORY OF BIOTECHNOLOGY 3) ETHANOL PRODUCTION SOARED, BUT U S FEDERAL SUBSIDY EXPIRES 4) CELLULOSIC ETHANOL MAKES SLOW COMMERCIAL PROGRESS 5) MAJOR DRUG COMPANIES ACQUIRE OR PARTNER WITH SMALLER BIOTECH FIRMS 6) FROM KOREA TO INDIA TO SINGAPORE TO CHINA, NATIONS COMPETE FIERCELY IN BIOTECH DEVELOPMENT 7) PATIENTS’ GENETIC PROFILES PLUMMET IN PRICE AS DNA SEQUENCING TECHNOLOGIES ADVANCE 8) GENE THERAPIES TARGET DEFECTIVE GENES/CRISPR ADVANCES DNA EDITING 9) VACCINES AND VIRUSES IN DRUG DELIVERY 10) NEW BLOCKBUSTER DRUGS COME TO MARKET/ DRUG PRICES SOAR/GENERICS OFFER SOME RELIEF 11) BIOTECH AND ORPHAN DRUGS CREATE NEW REVENUES FOR DRUG FIRMS 12) BIOSIMILARS (GENERIC BIOTECH DRUGS) RECEIVE FDA GUIDELINES FOR ACCELERATED APPROVAL/COMPETITION WILL BE FIERCE 13) DRUG DELIVERY SYSTEMS EVOLVE TO MEET THE NEEDS OF BIOTECH DRUGS 14) STEM CELLS—MULTIPLE SOURCES STEM FROM NEW TECHNOLOGIES 15) GOVERNMENT SUPPORT FOR STEM CELL RESEARCH EVOLVES 16) STEM CELLS—THERAPEUTIC CLONING TECHNIQUES ADVANCE 17) STEM CELLS—A NEW ERA OF TISSUE REPLACEMENT TAKES SHAPE 18) NANOTECHNOLOGY CONVERGES WITH BIOTECH 19) GENETICALLY MODIFIED (GM) SEEDS AND CROPS/R&D INVESTMENT IS HIGH 20) GENETICALLY MODIFIED (GM) INGREDIENTS IN PROCESSED OR PACKAGED FOODS 21) BIOPHARMING, DEVELOPMENT OF TRANSGENIC, PLANT-BASED PHARMACEUTICALS 22) CLONING OF FARM ANIMALS/MEAT AND CHEESE SUBSTITUTES CREATED IN LABORATORIES 23) SELECTIVE BREEDING, ZINC FINGERS AND MUTAGENESIS AS ALTERNATIVES TO GMOS 24) IMMUNOTHERAPY PROMISES NEW APPROACH TO FIGHTING CANCERS 25) TECHNOLOGY DISCUSSION—GENES AND DNA 26) TECHNOLOGY DISCUSSION—PROTEINS AND PROTEOMICS 27) TECHNOLOGY DISCUSSION—MICROARRAYS 28) TECHNOLOGY DISCUSSION—DNA CHIPS 29) TECHNOLOGY DISCUSSION—SNPS (“SNIPS”) 30) TECHNOLOGY DISCUSSION—COMBINATORIAL CHEMISTRY 31) TECHNOLOGY DISCUSSION—SYNTHETIC BIOLOGY 32) TECHNOLOGY DISCUSSION—RECOMBINANT DNA 33) TECHNOLOGY DISCUSSION—POLYMERASE CHAIN REACTION (PCR) CHAPTER 2: BIOTECH & GENETICS INDUSTRY STATISTICS BIOTECH INDUSTRY OVERVIEW THE U S DRUG DISCOVERY & APPROVAL PROCESS U S FDA NEW DRUG (NDA) AND BIOLOGIC (BLA) APPROVALS, EMPLOYMENT IN LIFE & PHYSICAL SCIENCE OCCUPATIONS BY BUSINESS TYPE, U S : MAY U S EXPORTS & IMPORTS OF PHARMACEUTICAL PRODUCTS: 2009-1ST QUARTER GLOBAL AREA OF BIOTECH CROPS BY COUNTRY SALES BY GEOGRAPHIC AREA, PHRMA MEMBER COMPANIES DOMESTIC U S BIOPHARMACEUTICAL R&D & R&D ABROAD BREAKDOWN, PHRMA MEMBER COMPANIES CHAPTER 3: IMPORTANT BIOTECH & GENETICS INDUSTRY CONTACTS (ADDRESSES, PHONE NUMBERS AND INTERNET SITES) CHAPTER 4: THE BIOTECH 400: WHO THEY ARE AND HOW THEY WERE CHOSEN INTRODUCTION PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC, THE FOURTEENTH EDITION OF OUR GUIDE TO THE BIOTECH AND GENETICS FIELD, IS DESIGNED TO BE USED AS A GENERAL SOURCE FOR RESEARCHERS OF ALL TYPES THE DATA AND AREAS OF INTEREST COVERED ARE INTENTIONALLY BROAD, RANGING FROM THE ETHICAL QUESTIONS FACING BIOTECHNOLOGY, TO EMERGING TECHNOLOGY, TO AN IN-DEPTH LOOK AT THE MAJOR FOR-PROFIT FIRMS (WHICH WE CALL “THE BIOTECH 400”) WITHIN THE MANY INDUSTRY SECTORS THAT MAKE UP THE BIOTECHNOLOGY AND GENETICS ARENA THIS REFERENCE BOOK IS DESIGNED TO BE A GENERAL SOURCE FOR RESEARCHERS IT IS ESPECIALLY INTENDED TO ASSIST WITH MARKET RESEARCH, STRATEGIC PLANNING, EMPLOYMENT SEARCHES, CONTACT OR PROSPECT LIST CREATION AND FINANCIAL RESEARCH, AND AS A DATA RESOURCE FOR EXECUTIVES AND STUDENTS OF ALL TYPES PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC TAKES A ROUNDED APPROACH FOR THE GENERAL READER THIS BOOK PRESENTS A COMPLETE OVERVIEW OF THE ENTIRE BIOTECHNOLOGY AND GENETICS SYSTEM (SEE “HOW TO USE THIS BOOK”) FOR EXAMPLE, YOU WILL FIND TRENDS IN THE BIOPHARMACEUTICALS MARKET, ALONG WITH EASY-TO-USE CHARTS AND TABLES ON ALL FACETS OF BIOTECHNOLOGY IN GENERAL: FROM THE SALES AND PROFITS OF THE MAJOR DRUG COMPANIES TO THE VARIOUS STAGES OF THE DRUG APPROVAL PROCESS THE BIOTECH 400 IS OUR UNIQUE GROUPING OF THE BIGGEST, MOST SUCCESSFUL CORPORATIONS IN ALL SEGMENTS OF THE GLOBAL BIOTECHNOLOGY AND GENETICS INDUSTRY TENS OF THOUSANDS OF PIECES OF INFORMATION, GATHERED FROM A WIDE VARIETY OF SOURCES, HAVE BEEN RESEARCHED AND ARE PRESENTED IN A UNIQUE FORM THAT CAN BE EASILY UNDERSTOOD THIS SECTION INCLUDES THOROUGH INDEXES TO THE BIOTECH 400, BY GEOGRAPHY, INDUSTRY, SALES, BRAND NAMES, SUBSIDIARY NAMES AND MANY OTHER TOPICS (SEE CHAPTER 4 ) ESPECIALLY HELPFUL IS THE WAY IN WHICH PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC ENABLES READERS WHO HAVE NO BUSINESS OR SCIENTIFIC BACKGROUND TO READILY COMPARE THE FINANCIAL RECORDS AND GROWTH PLANS OF LARGE BIOTECH COMPANIES AND MAJOR INDUSTRY GROUPS YOU’LL SEE THE MID-TERM FINANCIAL RECORD OF EACH FIRM, ALONG WITH THE IMPACT OF EARNINGS, SALES AND STRATEGIC PLANS ON EACH COMPANY’S POTENTIAL TO FUEL GROWTH, TO SERVE NEW MARKETS AND TO PROVIDE INVESTMENT AND EMPLOYMENT OPPORTUNITIES NO OTHER SOURCE PROVIDES THIS BOOK’S EASY-TO- UNDERSTAND COMPARISONS OF GROWTH, EXPENDITURES, TECHNOLOGIES, CORPORATIONS AND MANY OTHER ITEMS OF GREAT IMPORTANCE TO PEOPLE OF ALL TYPES WHO MAY BE STUDYING THIS, ONE OF THE MOST EXCITING INDUSTRIES IN THE WORLD TODAY BY SCANNING THE DATA GROUPS AND THE UNIQUE INDEXES, YOU CAN FIND THE BEST INFORMATION TO FIT YOUR PERSONAL RESEARCH NEEDS THE MAJOR GROWTH COMPANIES IN BIOTECHNOLOGY AND GENETICS ARE PROFILED WHICH FIRMS ARE THE BIGGEST EMPLOYERS? WHICH COMPANIES EARN THE MOST PROFITS? THESE THINGS AND MUCH MORE ARE EASY TO FIND IN ADDITION TO INDIVIDUAL COMPANY PROFILES, AN OVERVIEW OF BIOTECHNOLOGY MARKETS AND TRENDS IS PROVIDED THIS BOOK’S JOB IS TO HELP YOU SORT THROUGH EASY-TO-UNDERSTAND SUMMARIES OF TODAY’S TRENDS IN A QUICK AND EFFECTIVE MANNER WHATEVER YOUR PURPOSE FOR RESEARCHING THE BIOTECHNOLOGY AND GENETICS FIELD, YOU’LL FIND THIS BOOK TO BE A VALUABLE GUIDE NONETHELESS, AS IS TRUE WITH ALL RESOURCES, THIS VOLUME HAS LIMITATIONS THAT THE READER SHOULD BE AWARE OF: FINANCIAL DATA AND OTHER CORPORATE INFORMATION CAN CHANGE QUICKLY A BOOK OF THIS TYPE CAN BE NO MORE CURRENT THAN THE DATA THAT WAS AVAILABLE AS OF THE TIME OF EDITING CONSEQUENTLY, THE FINANCIAL PICTURE, MANAGEMENT AND OWNERSHIP OF THE FIRM(S) YOU ARE STUDYING MAY HAVE CHANGED SINCE THE DATE OF THIS BOOK FOR EXAMPLE, THIS ALMANAC INCLUDES THE MOST UP-TO-DATE SALES FIGURES AND PROFITS AVAILABLE TO THE EDITORS AS OF MID-2015 THAT MEANS THAT WE HAVE TYPICALLY USED CORPORATE FINANCIAL DATA AS OF LATE 2014 CORPORATE MERGERS, ACQUISITIONS AND DOWNSIZING ARE OCCURRING AT A VERY RAPID RATE SUCH EVENTS MAY HAVE CREATED SIGNIFICANT CHANGE, SUBSEQUENT TO THE PUBLISHING OF THIS BOOK, WITHIN A COMPANY YOU ARE STUDYING SOME OF THE COMPANIES IN THE BIOTECH ARE SO LARGE IN SCOPE AND IN VARIETY OF BUSINESS ENDEAVORS CONDUCTED WITHIN A PARENT ORGANIZATION, THAT WE HAVE BEEN UNABLE TO COMPLETELY LIST ALL SUBSIDIARIES, AFFILIATIONS, DIVISIONS AND ACTIVITIES WITHIN A FIRM’S CORPORATE STRUCTURE THIS VOLUME IS INTENDED TO BE A GENERAL GUIDE TO A VAST INDUSTRY THAT MEANS THAT RESEARCHERS SHOULD LOOK TO THIS BOOK FOR AN OVERVIEW AND, WHEN CONDUCTING IN-DEPTH RESEARCH, SHOULD CONTACT THE SPECIFIC CORPORATIONS OR INDUSTRY ASSOCIATIONS IN QUESTION FOR THE VERY LATEST CHANGES AND DATA WHERE POSSIBLE, WE HAVE LISTED CONTACT NAMES, TOLL-FREE TELEPHONE NUMBERS AND INTERNET SITE ADDRESSES FOR THE COMPANIES, GOVERNMENT AGENCIES AND INDUSTRY ASSOCIATIONS INVOLVED SO THAT THE READER MAY GET FURTHER DETAILS WITHOUT UNNECESSARY DELAY TABLES OF INDUSTRY DATA AND STATISTICS USED IN THIS BOOK INCLUDE THE LATEST NUMBERS AVAILABLE AT THE TIME OF PRINTING, GENERALLY THROUGH 2014 IN A FEW CASES, THE ONLY COMPLETE DATA AVAILABLE WAS FOR EARLIER YEARS WE HAVE USED EXHAUSTIVE EFFORTS TO LOCATE AND FAIRLY PRESENT ACCURATE AND COMPLETE DATA HOWEVER, WHEN USING THIS BOOK OR ANY OTHER SOURCE FOR BUSINESS AND INDUSTRY INFORMATION, THE READER SHOULD USE CAUTION AND DILIGENCE BY CONDUCTING FURTHER RESEARCH WHERE IT SEEMS APPROPRIATE WE WISH YOU SUCCESS IN YOUR ENDEAVORS, AND WE TRUST THAT YOUR EXPERIENCE WITH THIS BOOK WILL BE BOTH SATISFACTORY AND PRODUCTIVE JACK W PLUNKETT HOUSTON, TEXAS AUGUST PLUNKETT S BIOTECH AND GENETICS INDUSTRY ALMANAC 2003 HOW TO USE THIS BOOK THE TWO PRIMARY SECTIONS OF THIS BOOK ARE DEVOTED FIRST TO THE BIOTECHNOLOGY AND GENETICS INDUSTRY AS A WHOLE AND THEN TO THE “INDIVIDUAL DATA LISTINGS” FOR THE BIOTECH 400 IF TIME PERMITS, YOU SHOULD BEGIN YOUR RESEARCH IN THE FRONT CHAPTERS OF THIS BOOK ALSO, YOU WILL FIND LENGTHY INDEXES IN CHAPTER 4 AND IN THE BACK OF THE BOOK › VIDEO TIP FOR OUR BRIEF VIDEO INTRODUCTION TO THE BIOTECH INDUSTRY, SEE WWW PLUNKETTRESEARCH COM/VIDEO/BIOTECH THE BIOTECH AND GENETICS INDUSTRY CHAPTER 1: MAJOR TRENDS AFFECTING THE BIOTECH & GENETICS INDUSTRY THIS CHAPTER PRESENTS AN ENCAPSULATED VIEW OF THE MAJOR TRENDS AND TECHNOLOGIES THAT ARE CREATING RAPID CHANGES IN THE BIOTECHNOLOGY AND GENETICS INDUSTRY TODAY CHAPTER 2: BIOTECH & GENETICS INDUSTRY STATISTICS THIS CHAPTER PRESENTS IN-DEPTH STATISTICS ON BIOTECHNOLOGY MARKETS, SPENDING, RESEARCH, PHARMACEUTICALS AND MORE CHAPTER 3: IMPORTANT BIOTECH & GENETICS INDUSTRY CONTACTS – ADDRESSES, TELEPHONE NUMBERS AND INTERNET SITES THIS CHAPTER COVERS CONTACTS FOR IMPORTANT GOVERNMENT AGENCIES, BIOTECH ORGANIZATIONS AND TRADE GROUPS INCLUDED ARE NUMEROUS IMPORTANT INTERNET SITES THE BIOTECH CHAPTER 4: THE BIOTECH 400: WHO THEY ARE AND HOW THEY WERE CHOSEN THE COMPANIES COMPARED IN THIS BOOK WERE CAREFULLY SELECTED FROM THE BIOTECH AND GENETICS INDUSTRY, LARGELY IN THE UNITED STATES 124 OF THE FIRMS ARE BASED OUTSIDE THE U S FOR A COMPLETE DESCRIPTION, SEE THE BIOTECH 400 INDEXES IN THIS CHAPTER INDIVIDUAL DATA LISTINGS: LOOK AT ONE OF THE COMPANIES IN THE BIOTECH 400’S INDIVIDUAL DATA LISTINGS YOU’LL FIND THE FOLLOWING INFORMATION FIELDS: COMPANY NAME: THE COMPANY PROFILES ARE IN ALPHABETICAL ORDER BY COMPANY NAME IF YOU DON’T FIND THE COMPANY YOU ARE SEEKING, IT MAY BE A SUBSIDIARY OR DIVISION OF ONE OF THE FIRMS COVERED IN THIS BOOK TRY LOOKING IT UP IN THE INDEX BY SUBSIDIARIES, BRAND NAMES AND SELECTED AFFILIATIONS IN THE BACK OF THE BOOK INDUSTRY CODE: INDUSTRY GROUP CODE: AN NAIC CODE USED TO GROUP COMPANIES WITHIN LIKE SEGMENTS TYPES OF BUSINESS: A LISTING OF THE PRIMARY TYPES OF BUSINESS SPECIALTIES CONDUCTED BY THE FIRM BRANDS/DIVISIONS/AFFILIATIONS: MAJOR BRAND NAMES, OPERATING DIVISIONS OR SUBSIDIARIES OF THE FIRM, AS WELL AS MAJOR CORPORATE AFFILIATIONS—SUCH AS ANOTHER FIRM THAT OWNS A SIGNIFICANT PORTION OF THE COMPANY’S STOCK A COMPLETE INDEX BY SUBSIDIARIES, BRAND NAMES AND SELECTED AFFILIATIONS IS IN THE BACK OF THE BOOK CONTACTS: THE NAMES AND TITLES UP TO 27 TOP OFFICERS OF THE COMPANY ARE LISTED, INCLUDING HUMAN RESOURCES CONTACTS GROWTH PLANS/ SPECIAL FEATURES: LISTED HERE ARE OBSERVATIONS REGARDING THE FIRM’S STRATEGY, HIRING PLANS, PLANS FOR GROWTH AND PRODUCT DEVELOPMENT, ALONG WITH GENERAL INFORMATION REGARDING A COMPANY’S BUSINESS AND PROSPECTS FINANCIAL DATA: REVENUE (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE REPRESENTS CONSOLIDATED WORLDWIDE SALES FROM ALL OPERATIONS THESE NUMBERS MAY BE ESTIMATES R&D EXPENSE (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE REPRESENTS EXPENSES ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF A COMPANY’S GOODS OR SERVICES THESE NUMBERS MAY BE ESTIMATES OPERATING INCOME (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE REPRESENTS THE AMOUNT OF PROFIT REALIZED FROM ANNUAL OPERATIONS AFTER DEDUCTING OPERATING EXPENSES INCLUDING COSTS OF GOODS SOLD, WAGES AND DEPRECIATION THESE NUMBERS MAY BE ESTIMATES OPERATING MARGIN % (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE IS A RATIO DERIVED BY DIVIDING OPERATING INCOME BY NET REVENUES IT IS A MEASUREMENT OF A FIRM’S PRICING STRATEGY AND OPERATING EFFICIENCY THESE NUMBERS MAY BE ESTIMATES SGA EXPENSE (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE REPRESENTS THE SUM OF SELLING, GENERAL AND ADMINISTRATIVE EXPENSES OF A COMPANY, INCLUDING COSTS SUCH AS WARRANTY, ADVERTISING, INTEREST, PERSONNEL, UTILITIES, OFFICE SPACE RENT, ETC THESE NUMBERS MAY BE ESTIMATES NET INCOME (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE REPRESENTS CONSOLIDATED, AFTER-TAX NET PROFIT FROM ALL OPERATIONS THESE NUMBERS MAY BE ESTIMATES OPERATING CASH FLOW (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE IS A MEASURE OF THE AMOUNT OF CASH GENERATED BY A FIRM’S NORMAL BUSINESS OPERATIONS IT IS CALCULATED AS NET INCOME BEFORE DEPRECIATION AND AFTER INCOME TAXES, ADJUSTED FOR WORKING CAPITAL IT IS A PRIME INDICATOR OF A COMPANY’S ABILITY TO GENERATE ENOUGH CASH TO PAY ITS BILLS THESE NUMBERS MAY BE ESTIMATES CAPITAL EXPENDITURE (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE REPRESENTS FUNDS USED FOR INVESTMENT IN OR IMPROVEMENT OF PHYSICAL ASSETS SUCH AS OFFICES, EQUIPMENT OR FACTORIES AND THE PURCHASE OR CREATION OF NEW FACILITIES AND/OR EQUIPMENT THESE NUMBERS MAY BE ESTIMATES EBITDA (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE IS AN ACRONYM FOR EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION IT REPRESENTS A COMPANY'S FINANCIAL PERFORMANCE CALCULATED AS REVENUE MINUS EXPENSES (EXCLUDING TAXES, DEPRECIATION AND INTEREST), AND IS A PRIME INDICATOR OF PROFITABILITY THESE NUMBERS MAY BE ESTIMATES RETURN ON ASSETS % (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE IS AN INDICATOR OF THE PROFITABILITY OF A COMPANY RELATIVE TO ITS TOTAL ASSETS IT IS CALCULATED BY DIVIDING ANNUAL NET EARNINGS BY TOTAL ASSETS THESE NUMBERS MAY BE ESTIMATES RETURN ON EQUITY % (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): THIS FIGURE IS A MEASUREMENT OF NET INCOME AS A PERCENTAGE OF SHAREHOLDERS' EQUITY IT IS ALSO CALLED THE RATE OF RETURN ON THE OWNERSHIP INTEREST IT IS A VITAL INDICATOR OF THE QUALITY OF A COMPANY’S OPERATIONS THESE NUMBERS MAY BE ESTIMATES DEBT TO EQUITY (2014 OR THE LATEST FISCAL YEAR AVAILABLE TO THE EDITORS, PLUS UP TO FIVE PREVIOUS YEARS): A RATIO OF THE COMPANY’S LONG-TERM DEBT TO ITS SHAREHOLDERS’ EQUITY THIS IS AN INDICATOR OF THE OVERALL FINANCIAL LEVERAGE OF THE FIRM THESE NUMBERS MAY BE ESTIMATES ADDRESS: THE FIRM’S FULL HEADQUARTERS ADDRESS, THE HEADQUARTERS TELEPHONE, PLUS TOLL-FREE AND FAX NUMBERS WHERE AVAILABLE ALSO PROVIDED IS THE WORLD WIDE WEB SITE ADDRESS PLUNKETT S BIOTECH AND GENETICS INDUSTRY ALMANAC 2003 STOCK TICKER, EXCHANGE: WHEN AVAILABLE, THE UNIQUE STOCK MARKET SYMBOL USED TO IDENTIFY THIS FIRM’S COMMON STOCK FOR TRADING AND TRACKING PURPOSES IS INDICATED WHERE APPROPRIATE, THIS FIELD MAY CONTAIN “PRIVATE” OR “SUBSIDIARY” RATHER THAN A TICKER SYMBOL IF THE FIRM IS A PUBLICLY-HELD COMPANY HEADQUARTERED OUTSIDE OF THE U S , ITS INTERNATIONAL TICKER AND EXCHANGE ARE GIVEN TOTAL NUMBER OF EMPLOYEES: THE APPROXIMATE TOTAL NUMBER OF EMPLOYEES, WORLDWIDE, AS OF THE END OF 2014 (OR THE LATEST DATA AVAILABLE TO THE EDITORS) PARENT COMPANY: IF THE FIRM IS A SUBSIDIARY, ITS PARENT COMPANY IS LISTED SALARIES/BONUSES: (THE FOLLOWING DESCRIPTIONS GENERALLY APPLY TO U S EMPLOYERS ONLY ) HIGHEST EXECUTIVE SALARY: THE HIGHEST EXECUTIVE SALARY PAID, TYPICALLY A 2014 AMOUNT (OR THE LATEST YEAR AVAILABLE TO THE EDITORS) AND TYPICALLY PAID TO THE CHIEF EXECUTIVE OFFICER HIGHEST EXECUTIVE BONUS: THE APPARENT BONUS, IF ANY, PAID TO THE ABOVE PERSON SECOND HIGHEST EXECUTIVE SALARY: THE NEXT- HIGHEST EXECUTIVE SALARY PAID, TYPICALLY A AMOUNT (OR THE LATEST YEAR AVAILABLE TO THE EDITORS) AND TYPICALLY PAID TO THE PRESIDENT OR CHIEF OPERATING OFFICER SECOND HIGHEST EXECUTIVE BONUS: THE APPARENT BONUS, IF ANY, PAID TO THE ABOVE PERSON OTHER THOUGHTS: ESTIMATED FEMALE OFFICERS OR DIRECTORS: IT IS DIFFICULT TO OBTAIN THIS INFORMATION ON AN EXACT BASIS, AND EMPLOYERS GENERALLY DO NOT DISCLOSE THE DATA IN A PUBLIC WAY HOWEVER, WE HAVE INDICATED WHAT OUR BEST EFFORTS REVEAL TO BE THE APPARENT NUMBER OF WOMEN WHO EITHER ARE IN THE POSTS OF CORPORATE OFFICERS OR SIT ON THE BOARD OF DIRECTORS THERE IS A WIDE VARIANCE FROM COMPANY TO COMPANY HOT SPOT FOR ADVANCEMENT FOR WOMEN/MINORITIES: A “Y” IN APPROPRIATE FIELDS INDICATES “YES ” THESE ARE FIRMS THAT APPEAR EITHER TO HAVE POSTED A SUBSTANTIAL NUMBER OF WOMEN AND/OR MINORITIES TO HIGH POSTS OR THAT APPEAR TO HAVE A GOOD RECORD OF GOING OUT OF THEIR WAY TO RECRUIT, TRAIN, PROMOTE AND RETAIN WOMEN OR MINORITIES (SEE THE INDEX OF HOT SPOTS FOR WOMEN AND MINORITIES IN THE BACK OF THE BOOK ) THIS INFORMATION MAY CHANGE FREQUENTLY AND CAN BE DIFFICULT TO OBTAIN AND VERIFY CONSEQUENTLY, THE READER SHOULD USE CAUTION AND CONDUCT FURTHER INVESTIGATION WHERE APPROPRIATE GLOSSARY: A SHORT LIST OF BIOTECH AND GENETICS INDUSTRY TERMS PLUNKETT S BIOTECH AND GENETICS INDUSTRY ALMANAC 2003 CHAPTER MAJOR TRENDS AFFECTING THE BIOTECH & GENETICS INDUSTRY TRENDS AFFECTING THE BIOTECHNOLOGY & GENETICS INDUSTRY: 1) THE STATE OF THE BIOTECHNOLOGY INDUSTRY TODAY 2) A SHORT HISTORY OF BIOTECHNOLOGY 3) ETHANOL PRODUCTION SOARED, BUT U S FEDERAL SUBSIDY EXPIRES 4) CELLULOSIC ETHANOL MAKES SLOW COMMERCIAL PROGRESS 5) MAJOR DRUG COMPANIES ACQUIRE OR PARTNER WITH SMALLER BIOTECH FIRMS 6) FROM KOREA TO INDIA TO SINGAPORE TO CHINA, NATIONS COMPETE FIERCELY IN BIOTECH DEVELOPMENT 7) PATIENTS’ GENETIC PROFILES PLUMMET IN PRICE AS DNA SEQUENCING TECHNOLOGIES ADVANCE 8) GENE THERAPIES TARGET DEFECTIVE GENES/CRISPR ADVANCES DNA EDITING 9) VACCINES AND VIRUSES IN DRUG DELIVERY 10) NEW BLOCKBUSTER DRUGS COME TO MARKET/ DRUG PRICES SOAR/GENERICS OFFER SOME RELIEF 11) BIOTECH AND ORPHAN DRUGS CREATE NEW REVENUES FOR DRUG FIRMS 12) BIOSIMILARS (GENERIC BIOTECH DRUGS) RECEIVE FDA GUIDELINES FOR ACCELERATED APPROVAL/COMPETITION WILL BE FIERCE 13) DRUG DELIVERY SYSTEMS EVOLVE TO MEET THE NEEDS OF BIOTECH DRUGS 14) STEM CELLS—MULTIPLE SOURCES STEM FROM NEW TECHNOLOGIES 15) GOVERNMENT SUPPORT FOR STEM CELL RESEARCH EVOLVES 16) STEM CELLS—THERAPEUTIC CLONING TECHNIQUES ADVANCE 17) STEM CELLS—A NEW ERA OF TISSUE REPLACEMENT TAKES SHAPE 18) NANOTECHNOLOGY CONVERGES WITH BIOTECH 19) GENETICALLY MODIFIED (GM) SEEDS AND CROPS/R&D INVESTMENT IS HIGH 20) GENETICALLY MODIFIED (GM) INGREDIENTS IN PROCESSED OR PACKAGED FOODS 21) BIOPHARMING, DEVELOPMENT OF TRANSGENIC, PLANT-BASED PHARMACEUTICALS 22) CLONING OF FARM ANIMALS/MEAT AND CHEESE SUBSTITUTES CREATED IN LABORATORIES 23) SELECTIVE BREEDING, ZINC FINGERS AND MUTAGENESIS AS ALTERNATIVES TO GMOS 24) IMMUNOTHERAPY PROMISES NEW APPROACH TO FIGHTING CANCERS 25) TECHNOLOGY DISCUSSION—GENES AND DNA 26) TECHNOLOGY DISCUSSION—PROTEINS AND PROTEOMICS 27) TECHNOLOGY DISCUSSION—MICROARRAYS 28) TECHNOLOGY DISCUSSION—DNA CHIPS 29) TECHNOLOGY DISCUSSION—SNPS (“SNIPS”) 30) TECHNOLOGY DISCUSSION—COMBINATORIAL CHEMISTRY 31) TECHNOLOGY DISCUSSION—SYNTHETIC BIOLOGY 32) TECHNOLOGY DISCUSSION—RECOMBINANT DNA 33) TECHNOLOGY DISCUSSION—POLYMERASE CHAIN REACTION (PCR)